Basic Information
| LncRNA/CircRNA Name | LINC01638 |
| Synonyms | NA |
| Region | GRCh38_22: 27221349-27224727 |
| Ensemble | ENSG00000233521 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR, Western blot assay, ChIP, Luciferase reporter assay, RIP |
| Sample | cell lines (MCF-10A, T47D, MCF7, BT474, SKBR3, ZR-75-30, ZR-75-1, MDA-MB-231, BT549, and HCC1937), fresh breast tumor and adjacent non-cancerous breast tissue |
| Expression Pattern | up-regulated |
| Function Description | LINC01638 is highly expressed in TNBC tissues and cells.Mechanistically, LINC01638 interacts with c-Myc to prevent SPOP-mediated c-Myc ubiquitination and degradation. C-Myc transcriptionally enhances MTDH (metadherin) expression and subsequently activates Twist1 expression to induce EMT. Analysis of the epithelial marker E-cadherin and mesenchymal markers Vimentin and EMT-associated transcription factor Twist1 revealed that LINC01638 knockdown increased E-cadherin and reduced Vimentin and Twist1 expression at the mRNA (Fig. 2g) and protein (Fig. 2h) levels in MDA-MB-231 and BT549 cells, whereas LINC01638 overexpression showed an inverse effect in T47D cells (Fig. 2g, h). |
| Pubmed ID | 30002443 |
| Year | 2018 |
| Title | LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer. |
External Links
| Links for LINC01638 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |